Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to $118000.0.

  • Cyclerion Therapeutics' Share-based Compensation fell 1449.28% to $118000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $468000.0, marking a year-over-year decrease of 2277.23%. This contributed to the annual value of $625000.0 for FY2024, which is 4142.46% down from last year.
  • Latest data reveals that Cyclerion Therapeutics reported Share-based Compensation of $118000.0 as of Q3 2025, which was down 1449.28% from $114000.0 recorded in Q2 2025.
  • Cyclerion Therapeutics' 5-year Share-based Compensation high stood at $2.5 million for Q4 2021, and its period low was $103000.0 during Q4 2023.
  • Its 5-year average for Share-based Compensation is $942157.9, with a median of $379000.0 in 2023.
  • Its Share-based Compensation has fluctuated over the past 5 years, first plummeted by 9083.63% in 2023, then soared by 1844.66% in 2024.
  • Over the past 5 years, Cyclerion Therapeutics' Share-based Compensation (Quarter) stood at $2.5 million in 2021, then tumbled by 55.87% to $1.1 million in 2022, then plummeted by 90.84% to $103000.0 in 2023, then grew by 18.45% to $122000.0 in 2024, then dropped by 3.28% to $118000.0 in 2025.
  • Its Share-based Compensation stands at $118000.0 for Q3 2025, versus $114000.0 for Q2 2025 and $114000.0 for Q1 2025.